Curcumin: Getting back to the roots

Annals of the New York Academy of Sciences

Volumn 1056, Issue , 2005, Pages 206-217

  Shishodia, Shishir ^a   Sethi, Gautam ^a   Aggarwal, Bharat B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anti tumor; Antioxidant; Curcumin; Curcumin analogs

Indexed keywords

2 HYDROXYNAPHTHYLCURCUMIN; 2' DEOXY 2' CURCUMINYLURIDINE; 4 HYDROXY 3 METHOXYBENZOIC ACID METHYL ESTER; 6 GINGEROL; BETA CATENIN; BJC 005; CELL ADHESION MOLECULE; CELL CYCLE PROTEIN; CHC 007; CHC 011; CURCUMIN; CURCUMINATE SODIUM; CYCLIN D1; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; DI O GLYCINOYLCURCUMIN; DIACETYLCURCUMIN; EARLY GROWTH RESPONSE FACTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GINGER EXTRACT; HEME OXYGENASE 1; HYDRAZINOCURCUMIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN P21; TETRAHYDROCURCUMIN; TOCOPHEROL CURCUMIN; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTHRITIS; CANCER; CARDIOVASCULAR DISEASE; CHINESE MEDICINE; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; CROTON; DIABETES MELLITUS; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; GINGER; HUMAN; INFLAMMATION; LUNG INJURY; MEDICINAL PLANT; NEPHROTOXICITY; NONHUMAN; OSTEOPOROSIS; PLANT ROOT; PROTEIN EXPRESSION; PSORIASIS; TRADITIONAL MEDICINE; TREATMENT INDICATION; TREATMENT OUTCOME;

CURCUMA LONGA; ZINGIBER; ZINGIBER OFFICINALE;

EID: 29744451509     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1352.010     Document Type: Conference Paper

References (53)

1. AGGARWAL, B.B., A. KUMAR & A.C. BHARTI. 2003. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 23: 363-398.
2. CHENG, A.L., C.H. Hsu, J.K. LIN, et al. 2001. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 21: 2895-2900.
3. AMMON, H.P. & M.A. WAHL. 1991. Pharmacology of Curcuma longa. Planta Med. 57: 1-7.
4. KHOPDE, S.M., K.I. PRIYADARSINI, P. VENKATESAN, et al. 1999. Free radical scavenging ability and antioxidant efficiency of curcumin and its substituted analogue. Biophys. Chem. 80:85-91.
5. ADAMS, B.K., J. CAI, J. ARMSTRONG, et al. 2005. EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism. Anticancer Drugs 16: 263-275.
6. AGGARWAL, B.B., A. KUMAR, M.S. AGGARWAL, et al. 2005. Curcumin derived from turmeric (Curcuma longa): a spice for all seasons. In Phytochemicals in Cancer Chemoprevention. P.D. Debasis Bagchi & H.G. Preuss, Eds. :349-387. CRC Press. New York.
7. HENG, M.C., M.K. SONG, J. HARKER, et al. 2000. Drug-induced suppression of phosphorylase kinase activity correlates with resolution of psoriasis as assessed by clinical, histological and immunohistochemical parameters. Br. J. Dermatol. 143: 937-949.
8. TOURKINA, E., P. GOOZ, J.C. OATES, et al. 2004. Curcumin-induced apoptosis in scleroderma lung fibroblasts: role of protein kinase cepsilon. Am. J. Respir. Cell Mol. Biol. 31: 28-35.
9. YANG, F., G.P. LIM, A.N. BEGUM, et al. 2005. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280:5892-5901.
10. UKIL, A., S. MAITY, S. KARMAKAR, et al. 2003. Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br. J. Pharmacol. 139: 209-218.
11. EGAN, M.E., M. PEARSON, S.A. WEINER, et al. 2004. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 304: 600-602.
12. BHARTI, A.C., N. DONATO & B.B. AGGARWAL. 2003. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J. Immunol. 171: 3863-3871.
13. Xu, J., Y. Fu & A. CHEN. 2003. Activation of peroxisome proliferator-activated receptor-gamma contributes to the inhibitory effects of curcumin on rat hepatic stellate cell growth. Am. J. Physiol. Gastrointest. Liver Physiol. 285: G20-30.
14. BHARTI, A.C., N. DONATO, S. SINGH, et al. 2003. Curcumin (diferuloylmethane) downregulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 101: 1053-1062.
15. MUKHOPADHYAY, A., C. BUESO-RAMOS, D. CHATTERJEE, et al. 2001. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 20: 7597-7609.
16. MUKHOPADHYAY, A., S. BANERJEE, L.J. STAFFORD, et al. 2002. Curcumin-induced suppression of cell proliferation correlates with downregulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. Oncogene 21: 8852-8862.
17. KHOPDE, S.M., K.I. PRIYADARSINI, S.N. GUHA, et al. 2000. Inhibition of radiation-induced lipid peroxidation by tetrahydrocurcumin: possible mechanisms by pulse radiolysis. Biosci. Biotechnol. Biochem. 64: 503-509.
18. VENKATESAN, P., M.K. UNNIKRISHNAN, S.M. KUMAR, et al. 2003. Effect of curcumin analogues on oxidation of haemoglobin and lysis of erythrocytes. Curr. Sci. 84: 74-78.
19. RAO, T.S., N. BASU & H.H. SIDDIQUI. 1982. Anti-inflammatory activity of curcumin analogues. Indian J. Med. Res. 77: 574-578.
20. KUMAR, A.P., G.E. GARCIA, R. GHOSH, et al. 2003. 4-Hydroxy-3- methoxybenzoic acid methyl ester: a curcumin derivative targets Akt/NF kappa B cell survival signaling pathway: potential for prostate cancer management. Neoplasia 5: 255-266.
21. HAHM, E.R., G. CHEON, J. LEE, et al. 2002. New and known symmetrical curcumin derivatives inhibit the formation of Fos-Jun-DNA complex. Cancer Lett. 184: 89-96.
22. BARTHELEMY, S., L. VERGNES, M. MOYNIER, et al. 1998. Curcumin and curcumin derivatives inhibit Tat-mediated transactivation of type 1 human immunodeficiency virus long terminal repeat. Res. Virol. 149: 43-52.
23. DOUGLAS, D.E. 1993. 4,4′-Diacetyl curcumin: in-vitro histamine-blocking activity. J. Pharm. Pharmacol. 45: 766.
24. JOHN, VD., G. KUTTAN & K. KRISHNANKUTTY. 2002. Anti-tumour studies of metal chelates of synthetic curcuminoids. J. Exp. Clin. Cancer Res. 21: 219-224.
25. SHIM, J.S., D.H. KIM, H.J. JUNG, et al. 2002. Hydrazinocurcumin, a novel synthetic curcumin derivative, is a potent inhibitor of endothelial cell proliferation. Bioorg. Med. Chem. 10: 2439-2444.
26. RUKKUMANI, R., K. ARUNA, P.S. VARMA, et al. 2004. Comparative effects of curcumin and an analog of curcumin on alcohol and PUFA induced oxidative stress. J. Pharm. Pharm. Sci. 7: 274-283.
27. MISHRA, S., S. TRIPATHI & K. MISRA. 2002. Synthesis of a novel anticancer prodrug designed to target telomerase sequence. Nucleic Acids Res. (Suppl.) 2: 277-278.
28. SELVAM, C., S.M. JACHAK, R. THILAGAVATHI, et al. 2005. Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammatory agents. Bioorg. Med. Chem. Lett. 15: 1793-1797.
29. GOMES DDE, C., L. V. ALEGRIO, M.E. DE LIMA, et al. 2002. Synthetic derivatives of curcumin and their activity against Leishmania amazonensis. Arzneimittelforschung 52: 120-124.
30. DINKOVA-KOSTOVA, A.T. & P. TALALAY. 1999. Relation of structure of curcumin analogs to their potencies as inducers of Phase 2 detoxification enzymes. Carcinogenesis 20: 911-914.
31. TONNESEN, H.H. & J.V. GREENHILL. 1992. Studies on curcumin and curcuminoids XXII: curcumin as a reducing agent and as a radical scavenger. Int. J. Pharm. 87: 79-87.
32. VAJRAGUPTA, O., P. BOONCHOONG & L.J. BERLINER. 2004. Manganese complexes of curcumin analogues: evaluation of hydroxyl radical scavenging ability, superoxide dismutase activity and stability towards hydrolysis. Free Radic. Res. 38: 303-314.
33. VENKATESAN, P. & M.N. RAO. 2000. Structure-activity relationships for the inhibition of lipid peroxidation and the scavenging of free radicals by synthetic symmetrical curcumin analogues. J. Pharm. Pharmacol. 52: 1123-1128.
34. SREEJAYAN, N. & M.N. RAO. 1996. Free radical scavenging activity of curcuminoids. Arzneimittelforschung 46: 169-171.
35. AHSAN, H., N. PARVEEN, N.U. KHAN, et al. 1999. Pro-oxidant, anti-oxidant and cleavage activities on DNA of curcumin and its derivatives demethoxycurcumin and bisdemethoxycurcumin. Chem. Biol. Interact. 121: 161-175.
36. KAWASHIMA, H., K. AKIMOTO, S. JAREONKITMONGKOL, et al. 1996. Inhibition of rat liver microsomal desaturases by curcumin and related compounds. Biosci. Biotechnol. Biochem. 60: 108-110.
37. SIMON, A., D.P. ALLAIS, J.L. DUROUX, et al. 1998. Inhibitory effect of curcuminoids on MCF-7 cell proliferation and structure-activity relationships. Cancer Lett. 129: 111-116.
38. ROBINSON, T.P., T. EHLERS, I.R. HUBBARD, et al. 2003. Design, synthesis, and biological evaluation of angiogenesis inhibitors: aromatic enone and dienone analogues of curcumin. Bioorg. Med. Chem. Lett. 13: 115-117.
39. KIM, S.O., J.K. KUNDU, Y.K. SHIN, et al. 2005. [6]-Gingerol inhibits COX-2 expression by blocking the activation of p38 MAP kinase and NF-kappaB in phorbol ester-stimulated mouse skin. Oncogene 24: 2558-2567.
40. KEUM, Y.S., J. KIM, K.H. LEE, et al. 2002. Induction of apoptosis and caspase-3 activation by chemopreventive [6]-paradol and structurally related compounds in KB cells. Cancer Lett. 177: 41-47.
41. MAHADY, G.B., S.L. PENDLAND, G.S. YUN, et al. 2003. Ginger (Zingiber officinale Roscoe) and the gingerols inhibit the growth of Cag A+ strains of Helicobacter pylori. Anticancer Res. 23: 3699-3702.
42. MASUDA, T., H. MATSUMURA, Y. OYAMA, et al. 1998. Synthesis of (+/-)-cassumunins A and B, new curcuminoid antioxidants having protective activity of the living cell against oxidative damage. J. Nat. Prod. 61: 609-613.
43. HONG, J., M. BOSE, J. Ju, et al. 2004. Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: effects on cytosolic phospholipase A(2), cyclooxygenases and 5-lipoxygenase. Carcinogenesis 25: 1671-1679.
44. MIYOSHI, N., Y. NAKAMURA, Y. UEDA, et al. 2003. Dietary ginger constituents, galanals A and B, are potent apoptosis inducers in human T lymphoma Jurkat cells. Cancer Lett. 199: 113-119.
45. PAN, M.H., W.L. CHANG, S.Y LIN-SHIAU, et al. 2001. Induction of apoptosis by garcinol and curcumin through cytochrome c release and activation of caspases in human leukemia HL-60 cells. J. Agric. Food Chem. 49: 1464-1474.
46. CHAINY, G.B., S.K. MANNA, M.M. CHATURVEDI, et al. 2000. Anethole blocks both early and late cellular responses transduced by tumor necrosis factor: effect on NF-kappaB, AP-1, JNK, MAPKK and apoptosis. Oncogene 19: 2943-2950.
47. CHUN, K.S., J.Y KANG, O.H. KIM, et al. 2002. Effects of yakuchinone A and yakuchinone B on the phorbol ester-induced expression of COX-2 and iNOS and activation of NF-kappaB in mouse skin. J. Environ. Pathol. Toxicol. Oncol. 21: 131-139.
48. FLYNN, D.L., M.F. RAFFERTY & A.M. BOCTOR. 1986. Inhibition of 5-hydroxy-eicosatetraenoic acid (5-HETE) formation in intact human neutrophils by naturally-occurring diarylheptanoids: inhibitory activities of curcuminoids and yakuchinones. Prostaglandins Leukot. Med. 22: 357-360.
49. FUJISAWA, S., T. ATSUMI, M. ISHIHARA, et al. 2004. Cytotoxicity, ROS-generation activity and radical-scavenging activity of curcumin and related compounds. Anticancer Res. 24: 563-569.
50. PAN, M.H., T.M. HUANG & J.K. LIN. 1999. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab. Dispos. 27: 486-494.
51. ISHIDA, J., H. OHTSU, Y. TACHIBANA, et al. 2002. Antitumor agents. Part 214: synthesis and evaluation of curcumin analogues as cytotoxic agents. Bioorg. Med. Chem. 10: 3481-3487.
52. SRIVIVASAN, A., V.P. MENON, V. PERIASWAMY, et al. 2003. Protection of pancreatic beta-cell by the potential antioxidant bis-o-hydroxycinnamoyl methane, analogue of natural curcuminoid in experimental diabetes. J. Pharm. Pharm. Sci. 6: 327-333.
53. OHTSU, H., Z. XIAO, J. ISHIDA, et al. 2002. Antitumor agents. 217. Curcumin analogues as novel androgen receptor antagonists with potential as anti-prostate cancer agents. J. Med. Chem. 45: 5037-5042.